Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis

Clinical and Experimental Immunology

Volumn 152, Issue 3, 2008, Pages 593-597

  Jochems, C ^a   Lagerquist, M ^a   Hakansson C ^a   Ohlsson, C ^a   Carlsten, H ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

BMD; CIA; Mice; Raloxifene

Indexed keywords

6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ANTIBODY; ANTIRHEUMATIC AGENT; COLLAGEN; COLLAGEN TYPE 2; CYTOKINE; INTERLEUKIN 6; RALOXIFENE;

ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; FEMALE; HISTOLOGY; LONG TERM CARE; MOUSE; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; POLYARTHRITIS; POSTMENOPAUSE; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT DURATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; INTERLEUKIN-6; MICE; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 43349097778     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2008.03660.x     Document Type: Article

References (23)

1. Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002 46 : 625 31.
2. Forsblad D'Elia H, Larsen A, Waltbrand E et al. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann Rheum Dis 2003 62 : 617 23.
3. Sinigaglia L, Nervetti A, Mela Q et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol 2000 27 : 2582 9.
4. Forsblad D'Elia H, Larsen A, Mattsson LA et al. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheumatol 2003 30 : 1456 63.
5. Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005 118 : 64 73.
6. Jochems C, Islander U, Kallkopf A, Lagerquist M, Ohlsson C, Carlsten H. Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis. Arthritis Rheum 2007 56 : 3261 70.
7. Holmdahl R, Jansson L, Larsson E, Rubin K, Klareskog L. Homologous type II collagen induces chronic and progressive arthritis in mice. Arthritis Rheum 1986 29 : 106 13.
8. Windahl SH, Vidal O, Andersson G, Gustafsson JA, Ohlsson C. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. J Clin Invest 1999 104 : 895 901.
9. Verdrengh M, Jonsson IM, Holmdahl R, Tarkowski A. Genistein as an anti-inflammatory agent. Inflamm Res 2003 52 : 341 6.
10. Helle M, Boeije L, Aarden LA. Functional discrimination between interleukin 6 and interleukin 1. Eur J Immunol 1988 18 : 1535 40.
11. Holmdahl R, Jansson L, Andersson M. Female sex hormones suppress development of collagen-induced arthritis in mice. Arthritis Rheum 1986 29 : 1501 9.
12. Jansson L, Holmdahl R. Oestrogen induced suppression of collagen arthritis. IV. Progesterone alone does not affect the course of arthritis but enhances the oestrogen-mediated therapeutic effect. J Reprod Immunol 1989 15 : 141 50.
13. Yamasaki D, Enokida M, Okano T, Hagino H, Teshima R. Effects of ovariectomy and estrogen replacement therapy on arthritis and bone mineral density in rats with collagen-induced arthritis. Bone 2001 28 : 634 40.
14. Cheung J, Mak YT, Papaioannou S, Evans BA, Fogelman I, Hampson G. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J Endocrinol 2003 177 : 423 33.
15. Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Eur Cytokine Netw 2007 18 : 148 53.
16. Messalli EM, Mainini G, Scaffa C et al. Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas 2007 56 : 38 44.
17. Hasegawa J, Nagashima M, Yamamoto M, Nishijima T, Katsumata S, Yoshino S. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. J Rheumatol 2003 30 : 474 9.
18. Valleala H, Laasonen L, Koivula MK et al. Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. J Rheumatol 2003 30 : 468 73.
19. Adachi JD, Bensen WG, Brown J et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997 337 : 382 7.
20. Yilmaz L, Ozoran K, Gunduz OH, Ucan H, Yucel M. Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. Rheumatol Int 2001 20 : 65 9.
21. Saag KG, Emkey R, Schnitzer TJ et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998 339 : 292 9.
22. Eastell R, Devogelaer JP, Peel NF et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 2000 11 : 331 7.
23. Wallach S, Cohen S, Reid DM et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000 67 : 277 85.